Arrowhead Pharmaceuticals, Inc. (ARWR) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Margin recovery • Cash volatility • Heavy leverage ARWR shows improving operating margins and healthy near-term liquidity but is constrained by high debt, volatile cash conversion, and elevated valuation that require sustained margin gains to justify the stock.
Price Behavior
Key Price Behavior Insights: • Above last month SMA • Recovery from $55 • Nearby low‑60s resistance Support Level: $55.01–$55.05 Resistance Level: $62.92–$63.60 ARWR trades at $61.03 above its last month SMA (~$58.70), showing a recovery from mid‑March lows near $55 and short‑term bullish momentum but with nearby resistance in the low‑to‑mid $60s and meaningful (~15%) short‑term volatility that warrants risk control.
Sentiment & News
Key News Insights: • plozasiran approval • two‑year data • concentrated catalysts Arrowhead is transitioning to a commercial-stage RNAi company after plozasiran approval and supportive two‑year data, with near-term clinical catalysts but mixed investor reactions and a cautious buy valuation.
AI Summary
Arrowhead has transitioned into a commercial‑stage biotech—reducing single‑asset clinical binary risk—but the investment now hinges on near‑term commercial execution (plozasiran payer coverage and accelerating product revenue over the next 2–4 quarters) to justify elevated valuation versus the material leverage and dilution risk from recent financings; if commercialization falters or 2026 pivotal readouts disappoint, expect rapid downside and potential dilutive raises, so size positions conservatively and set strict stops.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |